Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,364.00
Bid: 12,398.00
Ask: 12,400.00
Change: 268.00 (2.22%)
Spread: 2.00 (0.016%)
Open: 12,150.00
High: 12,440.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)-AstraZeneca Plc

22 May 2014 11:58

RNS Number : 8236H
JPMorgan Securities Plc
22 May 2014
 



FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc.

(d) Date dealing undertaken:

21 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

Pfizer Inc.

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Purchases

 

 

Sales

1,872,379

47

 

3,245,770

44.5006 GBP

 481.6000 SEK

 

44.5050 GBP

42.9150 GBP

 481.6000 SEK

 

43.1350 GBP

 

 (b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(GBP)

Ordinary Shares

 

 

Equity Swap

 

 

Long

 

 

 

 

Short

 

 

43.5900

 44.1011

 44.1956

 43.1950

 

 43.6198

 43.6207

 43.6972

 43.7032

 43.7033

 43.7800

 43.8450

 43.8913

 43.9593

 43.9902

 481.6193

496,996

 4,720

 2,852

 1,713,398

 

2,604

 1,365

 12,545

 1,515

 13,949

 11

 767,404

 12

 167

 898

 47

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

(GBP)

Type

e.g. American, European etc.

Expiry date

 

Option money paid/ received per unit

(GBP)

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

(GBP)

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

22 May 2014

Contact name:

Tung T Le

Telephone number:

020 7742 7272

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEREAESAASXLEFF
Date   Source Headline
20th Aug 20197:00 amRNSFarxiga met primary endpoint in landmark Phase III
19th Aug 20197:00 amRNSDirectorate Change
14th Aug 20197:00 amRNSLynparza Phase III PAOLA-1 trial met primary endpo
14th Aug 20197:00 amRNSCalquence granted US Breakthrough Therapy Designat
9th Aug 20199:28 amRNSAmendment: Tagrisso significantly improves overall
9th Aug 20197:00 amRNSTagrisso significantly improves overall survival
7th Aug 20197:00 amRNSLynparza Phase III PROfound trial in HRR*
5th Aug 20197:00 amRNSForxiga label updated in the EU in type-2 diabetes
1st Aug 20193:00 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSAZN: H1 2019 Results
15th Jul 20197:00 amRNSUpdate on US regulatory decision for Farxiga
12th Jul 20197:00 amRNSImfinzi granted US Orphan Drug Designation for
1st Jul 20193:00 pmRNSTotal Voting Rights
1st Jul 20197:00 amRNSForxiga receives positive EU CHMP opinion for
1st Jul 20197:00 amRNSFasenra receives positive EU CHMP opinion for self
27th Jun 20197:00 amRNSImfinzi improves overall survival at interim
19th Jun 20197:00 amRNSBreztri Aerosphere (PT010) approved in Japan for
19th Jun 20197:00 amRNSLynparza approved in Japan for 1st-line
19th Jun 20197:00 amRNSBevespi Aerosphere approved by the Japanese
18th Jun 20197:00 amRNSLynparza approved in the EU for 1st-line
17th Jun 20197:00 amRNSCalquence significantly prolonged the time patient
12th Jun 20194:45 pmRNSPublication of a Prospectus
6th Jun 20197:00 amRNSCalquence Phase III ELEVATE-TN trial met primary
5th Jun 201912:36 pmEQSHardman & Co Research: AstraZeneca: Where has all the cash gone?
3rd Jun 20193:00 pmRNSBlock listing Interim Review
3rd Jun 20193:00 pmRNSTotal Voting Rights
3rd Jun 20197:00 amRNSLynparza nearly doubled time patients lived with
10th May 20197:00 amRNSPooled analyses of the roxadustat global Phase III
8th May 20192:00 pmRNSDirector/PDMR Shareholding
8th May 201911:00 amRNSDirector Declaration
8th May 20197:00 amRNSTrastuzumab deruxtecan demonstrated clinically
7th May 20197:00 amRNSCalquence PhIII ASCEND trial met primary endpoint
3rd May 20197:00 amRNSQternmet XR approved in the US for type-2 diabetes
1st May 20193:00 pmRNSTotal Voting Rights
1st May 201912:00 pmRNSDirector/PDMR Shareholding
29th Apr 20197:00 amRNSLynparza receives positive EU CHMP opinion for 1st
26th Apr 20195:45 pmRNSResult of AGM
26th Apr 20197:00 amRNSAZN: Q1 2019 Results
10th Apr 20197:00 amRNSLynparza approved in EU for the treatment of germl
9th Apr 20194:10 pmEQSHardman & Co Research: Global Pharmaceuticals: 2018 industry sales
4th Apr 20191:30 pmRNSHolding(s) in Company
3rd Apr 201910:00 amRNSDirector/PDMR Shareholding
2nd Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20196:00 pmRNSAstrazeneca
1st Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20197:00 amRNSSelumetinib gets Breakthrough Therapy Designation
29th Mar 20195:15 pmRNSResults of Placing
29th Mar 20197:00 amRNSProposed placing of new ordinary shares
29th Mar 20197:00 amRNSAZ and Daiichi Sankyo enter collaboration in novel
27th Mar 20197:00 amRNSForxiga approved in Japan for type-1 diabetes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.